First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects

NCT05427253 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Safety Issues
Tolerance
Idiopathic Pulmonary Fibrosis
Pulmonary Hypertension

Interventions

DRUG: C106 solution
DRUG: Placebo

Sponsor

Vicore Pharma AB